---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003920"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:09:54.691896+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios outlines 2024 milestones; positive Phase 3 mitapivat data in thalassemia; multiple potential approvals by 2026

## Summary
- Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia met primary endpoint (data Jan 3, 2024).
- NDA for mitapivat in thalassemia planned by end of 2024; potential FDA approval in 2025.
- Four additional Phase 3 readouts expected by end of 2025: ENERGIZE-T, ACTIVATE kids-T, RISE UP, ACTIVATE kids.
- Potential FDA approvals: thalassemia 2025, sickle cell disease 2026, pediatric PK deficiency 2026.
- Cash position expected to support operations and pipeline expansion at least into 2026.

## SEC filing metadata
- accession: 0001193125-24-003920
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/0001193125-24-003920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312524003920/d275955d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003920
- JSON: https://secwatch.observer/filing/0001193125-24-003920.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.